FDA Approves Opdivo Plus Chemotherapy for Gastric Cancer

The U.S. Food and Drug Administration (FDA) has granted approval for nivolumab (Opdivo) in combination with chemotherapy as a first-line treatment for advanced or metastatic gastric cancer, including gastroesophageal junction adenocarcinoma. This FDA Opdivo approval signifies a notable advancement in the treatment of this aggressive cancer, offering improved survival outcomes compared to chemotherapy alone and reflects the growing importance of immuno-oncology in cancer care.

Drug Overview

Nivolumab (Opdivo) is a fully human IgG4 monoclonal antibody and a PD-1 immune checkpoint inhibitor. It works by blocking the interaction between PD-1 receptors on T cells and its ligands PD-L1 and PD-L2, thereby enhancing the anti-tumor immune response. It is approved for use in combination with chemotherapy as a first-line treatment for adults with unresectable locally advanced, recurrent, or metastatic gastric cancer, including gastroesophageal junction adenocarcinoma.

IntelligenceRegulatory Impact▾

FDA are the agencies to watch. Regulatory relevance reads medium for gastric cancer, with nivolumab most exposed to upcoming decisions. Teams should track submission types, designations, and guidance shifts that could move approval timelines.

Clinical Insights

The nivolumab approval is supported by clinical trials demonstrating improved overall survival and progression-free survival compared to chemotherapy alone. The trials enrolled patients with advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma. Key efficacy endpoints included overall survival (OS) and progression-free survival (PFS), both showing statistically significant improvement with the combination therapy. The safety profile was consistent with known adverse events of nivolumab and chemotherapy, with manageable side effects.

IntelligenceCompetitive Intelligence▾

Competitive pressure is low. Watch which sponsors move first. Benchmark pipeline positioning, differentiation, and partnership scouting against the signals in this story.

Regulatory Context

The nivolumab approval followed the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA). The approval was based on Phase 3 randomized controlled trials demonstrating clinical benefit. Post-marketing commitments and pharmacovigilance are standard.

IntelligenceMarket Signals▾

Commercial pull is medium and investment relevance low. Expect implications for gastric cancer pricing, access, and launch sequencing.

Market Impact

The introduction of nivolumab plus chemotherapy offers a novel first-line treatment option, potentially increasing market share in immuno-oncology and expanding therapeutic choices for gastric cancer. The gastric cancer market includes chemotherapy agents and targeted therapies like trastuzumab. Nivolumab expands options for HER2-negative or unselected patients, and provides improved survival benefits over chemotherapy alone, representing a significant advancement over existing chemotherapy and targeted therapy options.

IntelligenceStrategic Takeaways▾

The FDA has approved Opdivo in combination with chemotherapy for the treatment of gastric cancer, marking a significant advancement in cancer care.

Future Outlook

Ongoing studies may explore further combinations and indications in gastric and gastroesophageal cancers. The nivolumab approval may shift treatment paradigms by integrating immunotherapy with chemotherapy in earlier lines of therapy.

Frequently Asked Questions

References

References

1. U.S. Food and Drug Administration. FDA approval. Accessed 2026-04-02.

IntelligenceEvidence Quality▾

Claims are grounded in the cited primary and secondary sources, with editorial review applied before publication.

Related profiles

• nivolumab

Related coverage

• FDA approves Vyloy for HER2-negative gastric and GEJ cancer
• FDA approves Keytruda for adjuvant NSCLC treatment, expanding Merck’s lung cancer label
• FDA approves Keytruda adjuvant NSCLC use in early-stage lung cancer